Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

Myriad Genetics (MYGN) Tops Q3 EPS by 8c

May 3, 2021 4:37 PM EDT

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.06), $0.08 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $173.1 million versus the consensus estimate of $156.2 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

... More